Targeted drug shows promise for rare bone cancer
NCT ID NCT05041127
First seen Feb 20, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This phase 2 trial is testing whether cetuximab, a targeted antibody drug, can shrink tumors in people with advanced or metastatic chordoma, a rare type of bone cancer. About 29 adults with inoperable or spread chordoma will receive cetuximab intravenously. The main goal is to see how many patients respond to treatment, with safety also closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cetuximab (a targeted antibody drug given intravenously)
What this could lead to
If successful, this could provide a new treatment option for people with advanced chordoma, a rare bone cancer with limited therapies.
What could go wrong
This is a small, early-phase trial with only 29 participants and no comparison group, so results may not be conclusive. Cetuximab can cause skin reactions and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.